Rudebeck CJ, Fornecker LM, Guffroy B, Fouillet L, Chauchet A, Caillet A, Gros F-X, Brisou G, Manjra H, Camus V, Guidez S, Claves F, Beauvais D, Idlhaj M, Golfier C, Safar V, Ferrant E, Bachy E, Ghesquieres H, Sesques P. Outcomes of ibrutinib plus lenalidomide combination in patients with large B-cell lymphoma refractory to or relapsing after CAR-T-cell therapy and who failed or were ineligible for bispecific antibodies: a multicenter real-world REALI-T study. Haematologica; https://doi.org/10.3324/haematol.2026.300868 [Early view].